BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
52.01
-0.56 (-1.07%)
Aug 29, 2025, 10:47 AM - Market open
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 16 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $61.69, which forecasts a 18.61% increase in the stock price over the next year. The lowest target is $46 and the highest is $95.
Price Target: $61.69 (+18.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 7 | 7 |
| Buy | 6 | 6 | 6 | 8 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 14 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +9.59% | Aug 6, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $61 | Buy | Maintains | $60 → $61 | +17.29% | Aug 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $95 | Buy | Reiterates | $95 | +82.66% | Jul 29, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $66 | Strong Buy | Initiates | $66 | +26.90% | Jul 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $63 → $68 | Buy | Maintains | $63 → $68 | +30.74% | Jul 14, 2025 |
Financial Forecast
Revenue This Year
478.17M
from 221.90M
Increased by 115.49%
Revenue Next Year
787.10M
from 478.17M
Increased by 64.61%
EPS This Year
-3.43
from -2.88
EPS Next Year
-2.18
from -3.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 572.4M | 1.2B | |||
| Avg | 478.2M | 787.1M | |||
| Low | 380.2M | 525.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 157.9% | 146.8% | |||
| Avg | 115.5% | 64.6% | |||
| Low | 71.4% | 9.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.21 | -0.67 | |||
| Avg | -3.43 | -2.18 | |||
| Low | -3.79 | -3.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.